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Abstract
Arenaviruses are the causative pathogens of severe hemorrhagic fever and aseptic meningitis in humans, for which no
licensed vaccines are currently available. Pathogen heterogeneity within the Arenaviridae family poses a significant
challenge for vaccine development. The main hypothesis we tested in the present study was whether it is possible to design
a universal vaccine strategy capable of inducing simultaneous HLA-restricted CD8
+ T cell responses against 7 pathogenic
arenaviruses (including the lymphocytic choriomeningitis, Lassa, Guanarito, Junin, Machupo, Sabia, and Whitewater Arroyo
viruses), either through the identification of widely conserved epitopes, or by the identification of a collection of epitopes
derived from multiple arenavirus species. By inoculating HLA transgenic mice with a panel of recombinant vaccinia viruses
(rVACVs) expressing the different arenavirus proteins, we identified 10 HLA-A02 and 10 HLA-A03-restricted epitopes that are
naturally processed in human antigen-presenting cells. For some of these epitopes we were able to demonstrate cross-
reactive CD8
+ T cell responses, further increasing the coverage afforded by the epitope set against each different arenavirus
species. Importantly, we showed that immunization of HLA transgenic mice with an epitope cocktail generated
simultaneous CD8
+ T cell responses against all 7 arenaviruses, and protected mice against challenge with rVACVs expressing
either Old or New World arenavirus glycoproteins. In conclusion, the set of identified epitopes allows broad, non-ethnically
biased coverage of all 7 viral species targeted by our studies.
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Introduction
Pathogen heterogeneity is a commonly encountered challenge
for vaccine design. A considerable fraction of unmet vaccine needs
for infectious disease is associated with pathogens naturally
displaying significant levels of genetic diversity. In particular,
RNA viruses pose a substantial challenge because of their
propensity for rapid mutation and recombination. A prominent
example includes arenaviruses, which are categorized in different
complexes with distinct geographical locations, and continue to
provide a formidable challenge for vaccine development.
The Arenaviridae family, consisting of a single genus (Arenavirus),
contains 22 known viral species, which are classified phylogenet-
ically into Old World and New World complexes [1]. The latter
complex is further divided into three Clades (A, B, and C). Old
World viruses include Lassa virus (LASV) and the prototypic
arenavirus family member, lymphocytic choriomeningitis virus
(LCMV). The New World Clade B contains some of the most
pathogenic agents, including Guanarito virus (GTOV), Junin virus
(JUNV), Machupo virus (MACV), Sabia virus (SABV), and the
recombinant Clade A/B arenavirus, Whitewater Arroyo virus
(WWAV). Arenaviruses are enveloped viruses, with a ,10.7 kb
RNA genome that encodes four viral proteins, including the
glycoprotein precursor (GPC), nucleocapsid protein (NP), RNA-
dependent RNA polymerase (L), and the zinc-finger binding
protein (Z) [2].
Human infection with arenaviruses typically occurs through
direct contact with infected rodents or by inhalation of infectious
rodent excretions and secretions, and is associated with dehabil-
itating and sometimes life-threatening human disease, including
central nervous system damage, aseptic meningitis [3], congenital
deformities [4,5], and severe hemorrhagic fever syndrome
(reviewed in [6]). Despite the pathogenicity of arenaviruses, there
are no licensed vaccines available. Therefore, it is important to
develop novel prophylactic vaccine strategies to combat these
viruses. CD8
+ T cell responses have clearly been associated with
reduced pathology and protection against Old World arenavirus
infection in both murine models of infection [7,8,9,10] and in
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CD8
+ T cell-mediated immunity in countering New World
arenavirus infections in humans [13,14]. Thus, vaccination
strategies aimed at generating CD8
+ T cell responses against both
Old and New World arenaviruses should be considered.
The goals of the present study were to identify HLA-
restricted CD8
+ T cell epitopes from 7 different arenaviruses
associated with disease in humans, including GTOV, JUNV,
LASV, LCMV, MACV, SABV, and WWAV, and to develop
a universal vaccination strategy designed to elicit a T cell-
mediated immune response that would provide broad coverage
against a variety of arenaviruses and across different ethnic
populations. Because of the heterogeneity observed amongst
different species of arenaviruses, two non-mutually exclusive
concepts were explored. First, we wanted to address whether it
was possible to identify CD8
+ T cell epitopes that are
conserved and/or cross-reactive amongst the different arena-
virus species, and second, to determine whether it was possible
to combine in the same vaccine, epitopes derived from each of
the different arenavirus species, thus providing effective
multivalent protection. Here, we report the identification of
HLA-restricted CD8
+ T cell epitopes that were either cross-
reactive or species-specific, and demonstrate that immuniza-
tion with these epitopes protected HLA transgenic mice from
challenge with rVACV expressing antigens from different
arenavirus species.
Results
Generation of a set of rVACV expressing arenavirus
antigens
Because the majority of arenaviruses studied require biosafety
level-4 (BSL-4) containment, rVACV constructs were designed to
express the GPC, NP, L, or Z proteins from the 7 different
arenaviruses as a tool to induce and evaluate CD8
+ T cell
responses. The gene sequences encoding the different arenavirus
proteins were derived from prototypic virus strains (Table S1), and
the constructs were engineered into the Western Reserve (WR)
strain of VACV.
In total, individual rVACV constructs expressing 24 of the 28
arenavirus antigens of interest were generated. Arenavirus protein
expression was confirmed for each rVACV through Western blot
analysis with infected cell lysates. We verified that arenavirus
proteins of the correct size were reproducibly detected from each
construct (Figure S1 and data not shown). Although there were
different levels of expression for the GPC, L, NP, and Z proteins
within the same virus (as shown for GTOV in Figure S1), there
was relatively little variation in the level of expression of the same
viral protein across the 7 different arenavirus species. Protein
expression remained relatively consistent across similar viral
proteins as the large majority of arenavirus genes were under
the control of a synthetic early/late promoter, PSYN. Overall,
these results demonstrate that the 4 viral proteins from different
arenavirus species can be ectopically expressed within a rVACV.
We did not express WWAV L or Z protein because, at the
initiation of this study, sequences for these viral antigens were not
available. Technical difficulties also prevented the generation of
JUNV Z and SABV L constructs.
Bioinformatic selection of candidate arenavirus-derived
CD8
+ T cell epitopes
To identify candidate arenavirus-derived CD8
+ Tc e l l
epitopes, we screened the GPC, L, NP, and Z protein sequences
f r o mG T O V ,J U N V ,L A S V ,L C M V ,M A C V ,S A B V ,a n d
WWAV using bioinformatic algorithms described elsewhere
[15]. The HLA-A02 and HLA-A03 supertype specificities were
selected because together they should allow coverage of ,75% of
the human worldwide population [16], and because HLA
transgenic mice are available for these two HLA specificities
[17,18]. Because high HLA binding affinity is associated with
immunogenicity in vivo [19], peptides with a predicted affinity
of #100 nM were selected. To limit the number of candidates to
a manageable number we chose to study up to 30 different
peptides for each HLA/virus/antigen combination. In total, 481
HLA-A02 and 527 HLA-A03 unique candidate peptide sequenc-
es, consisting of nonamers and decamers, were selected and
synthesized.
Identification of HLA-A02-restricted arenavirus CD8
+ T
cell epitopes
Because human PBMC samples from arenavirus-exposed
individuals were difficult to obtain, we used HLA transgenic mice
to identify human arenavirus epitopes. To determine the in vivo
antigenicity of the 481 arenavirus peptides predicted to bind HLA-
A02, HLA-A*0201 transgenic mice were infected with rVACV
expressing one of the arenavirus proteins (see Materials and
Methods for details). Twelve different CD8
+ T cell epitopes from 6
arenavirus species were identified utilizing IFN-c ELISPOT
assays: 2 from JUNV (GPC7–15 and GPC18–26), 1 from LASV
(GPC111–120), 2 from LCMV (GPC34–43 and Z49–58), 3 from
MACV (GPC18–26,N P 19–27, and NP432–440), 2 from SABV
(GPC142–150 and NP547–556), and 2 from WWAV (GPC42–50 and
NP274–282) (Figure 1). The JUNV GPC18–26 epitope is 100%
conserved in MACV, and was independently identified as an
epitope in both viruses. A CD8
+ T cell epitope was not identified
from GTOV. None of the epitopes were recognized by CD8
+ T
cells derived HLA-A*0201 transgenic mice infected with wild type
(wt) VACV-WR.
As these 12 HLA-A*0201 epitopes were identified following
rVACV infection in transgenic mice, these experiments indicated
that they can be generated by processing in mouse antigen-
presenting cells (APCs). To assess processing in human APCs,
Author Summary
Arenaviruses cause significant morbidity and mortality
worldwide and are also regarded as a potential bioterrorist
threat. CD8
+ T cells restricted by class I MHC molecules
clearly play a protective role in murine models of
arenavirus infection, yet little is known about the epitopes
recognized in the context of human class I MHC (HLA).
Here, we defined 20 CD8
+ T cell epitopes restricted by HLA
class I molecules, derived from 7 different species of
arenaviruses associated with human disease. To accom-
plish this task, we utilized epitope predictions, in vitro HLA
binding assays, and HLA transgenic mice inoculated with
recombinant vaccinia viruses (rVACV) expressing arenavi-
rus antigens. Because our analysis targeted two of the
most common HLA types worldwide, we project that the
CD8
+ T cell epitope set provides broad coverage against
diverse ethnic groups within the human population.
Furthermore, we show that immunization with a cocktail
of these epitopes protects HLA transgenic mice from
challenge with rVACV expressing antigens from different
arenavirus species. Our findings suggest that a cell-
mediated vaccine strategy might be able to protect
against infection mediated by multiple arenavirus species.
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arenavirus epitopes individually, and 11 to 14 days post-
immunization, splenic CD8
+ T cells were assayed for recognition
of human target cells infected with the rVACV expressing the
appropriate arenavirus antigen. Recognition of rVACV-infected
target cells was robust for 7 of the 12 peptide-primed CD8
+ T cells
(LASV GPC111–120, LCMV Z49–58, MACV NP19–27, SABV
GPC142–150, SABV NP547–556, WWAV GPC42–50, and WWAV
NP274–282; Figure 2). Three epitopes (JUNV GPC18–26, MACV
GPC18–26, and MACV NP432–440) were weakly recognized in
replicate experiments, while for JUNV GPC7–15 and LCMV
GPC34–43 processing in human APCs could not be demonstrated.
None of the arenavirus peptide-primed CD8
+ T cells had a
detectable response to target cells infected with wt VACV-WR
(data not shown). We also observed minor recognition of 2
epitopes by murine H-2
bxd as LASV GPC111–120 and LCMV
GPC34–43 were presented by one of the endogenous mouse MHC
class I molecules co-expressed in the HLA-A*0201 transgenic mice
(data not shown). Table 1 provides an overall summary of the
properties of the arenavirus-derived HLA-A*0201-restricted CD8
+
T cell epitopes, including which epitopes were endogenously
processed in human APCs.
Identification of HLA-A03-restricted arenavirus CD8
+ T
cell epitopes
Peptides containing positively charged amino acids at the
carboxyl-termini associated with HLA-A03 supertype binding are
not effectively processed in mice [20]. To overcome this potential
problem, and enable the use of mice expressing the A03 supertype
prototype allele HLA-A*1101, the immunogenicity of the 527
predicted HLA-A03 binding peptides was determined by immu-
nization of HLA-A*1101 transgenic mice with pools of the
predicted arenavirus peptides. Using this strategy, we identified
165 HLA-A03 supertype peptides that were immunogenic in
HLA-A*1101 transgenic mice (data not shown).
To assess processing of the immunogenic HLA-A*1101
peptides, HLA-A*1101 transgenic mice were immunized with
individual arenavirus peptides (see Materials and Methods for
details). At 11 to 14 days post-immunization, splenic CD8
+ T cells
were screened for recognition of HLA-A*1101-expressing human
target cells that had been infected with an appropriate rVACV. It
was found that 14 of the 165 HLA-A*1101 peptides tested were
endogenously processed from native arenavirus antigens by
human APCs and recognized by arenavirus peptide-primed
CD8
+ T cells. Of these peptides, 4 were overlapping with the 14
Figure 1. Identification of antigenic arenavirus-derived peptides in HLA-A*0201 transgenic mice following rVACV infection. HLA-
A*0201 transgenic mice were immunized i.p. with either a rVACV expressing an arenavirus protein or wt VACV-WR as a control. Purified splenic CD8
+
T cells were isolated 7 days later and exposed to human JA2.1 target cells, expressing the HLA-A*0201/K
b chimeric gene, that had been pulsed with
0.1 mg/ml of each of the listed peptides in an ex vivo IFN-c ELISPOT assay. The dotted line indicates the threshold for peptide positivity (net SFC/10
6
cells $20). Representative responses of at least two independent experiments are shown. Error bars indicate SD.
doi:10.1371/journal.ppat.1000695.g001
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PLoS Pathogens | www.plospathogens.org 3 December 2009 | Volume 5 | Issue 12 | e1000695Figure 2. Natural processing of arenavirus peptides in HLA-A*0201-restricted human target cells that express native arenavirus
antigens. HLA-A*0201 transgenic mice were immunized s.c. with one of the listed peptides, and 11 to 14 days later splenic CD8
+ T cells were
isolated. Effector CD8
+ T cells were exposed to human JA2.1 cells that had been either pulsed with 1 mg/ml of the immunizing peptide, or infected
with the appropriate rVACV in an ex vivo IFN-c ELISPOT assay. The dotted line indicates the threshold for peptide positivity (net SFC/10
6 cells $20).
Error bars indicate SD. Data are representative of at least two independent experiments.
doi:10.1371/journal.ppat.1000695.g002
Table 1. Properties of arenavirus-derived HLA-A*0201-restricted CD8
+ T cell epitopes.
Arenavirus epitope
a Peptide sequence
% Identity to
parental species
b
Natural processing
in human APCs
c
Binding affinity
to A*0201 (nM)
d
JUNV GPC7–15 FMQEIPTFL 100 2 11
JUNV GPC18–26 ALNIALVAV 100 +/2 79
LASV GPC111–120 SIINHKFCNL 96 + 2123
LCMV GPC34–43 AVYNFATCGI 98 2 137
LCMV Z49–58 YLCRHCLNLL 99 + 3.9
MACV GPC18–26 ALNIALVAV 100 +/2 79
MACV NP19–27 GLSQFTHTV 94 + 18
MACV NP432–440 AMPGVLSYV 100 +/2 8.4
SABV GPC142–150 GLLEWIFRA 100 + 1.2
SABV NP547–556 LLPDALLFTL 100 + 77
WWAV GPC42–50 GLLQFIVFL 100 + ,0.05
WWAV NP274–282 TVIKTLLEV 100 + 276
aPeptide position within prototypic strains of arenavirus GPC, NP, L and Z proteins.
bAverage % amino acid identity of epitope sequence to all full-length isolate sequences within a given arenavirus species.
cEach peptide was screened for its ability to be endogenously processed and presented by HLA-A*0201. Purified CD8
+ T cells from peptide-immunized HLA-A*0201
mice were tested for recognition of human JA2.1 cells infected with the appropriate rVACV construct expressing one of the arenavirus proteins. +, Processed; +/2,
weakly processed; 2, not processed.
dPeptides were tested for binding to the HLA-A*0201 allele. Bold font highlights biologically relevant binders (IC50#500 nM). 2, peptides with binding affinity .
5000 nM.
doi:10.1371/journal.ppat.1000695.t001
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+ T cell
responses. Thus, in total, 10 unique epitopes were endogenously
processed by human APCs. These peptides represented all 4 viral
antigens and 5 different arenaviruses: 1 from GTOV (L1977–1985),
3 from LCMV (GPC46–55, GPC112–120 and Z24–33), 2 from MACV
(NP82–90 and Z27–36), 3 from SABV (GPC90–98,N P 82–90 and Z64–
72), and 1 from WWAV (NP439–447) (Figure 3). A homologous
epitope (NP82–90) was identified in both MACV and SABV. None
of the arenavirus peptide-primed CD8
+ T cells had a detectable
response to target cells infected with wt VACV-WR (data not
shown). In addition, a single determinant (LCMV GPC46–55) was
immunogenic when presented by either HLA-A*1101-expressing
or H-2
bxd-expressing APCs (data not shown). An overall summary
of the properties of the arenavirus-derived HLA-A*1101-restricted
CD8
+ T cell epitopes is provided in Table 2.
Identification of HLA-restricted epitopes that are cross-
reactive among multiple arenaviruses
The identified epitopes were 89 to 100% conserved within a
given arenavirus species (Tables 1 and 2). Next, we wanted to
determine whether the CD8
+ T cell responses generated by the
identified HLA-restricted epitopes could cross-reactively recognize
orthologous sequences derived from different arenavirus species.
Such cross-recognitionmightfurther increasethecoverage afforded
by the epitope set against each different arenavirus species.
To identify cross-reactive peptides, we compared the primary
amino acid sequence of the 12 HLA-A02 epitopes, and the 10
HLA-A03 epitopes identified herein, as well as the 3 LASV
(GPC42–50, GPC60–68, and GPC441–449) and 3 LCMV (GPC10–18,
GPC447–455, and NP69–77) HLA-A*0201-restricted epitopes iden-
tified in previous studies [9,10] to the orthologous regions within
the other arenavirus protein sequences used to generate the
rVACV constructs. Peptides containing 2 or more identical amino
acids as the epitope sequence and found in $20% of the isolates in
the arenavirus protein sequence database (http://epitope.liai.
org:8080/projects/arena) were chosen for further analysis. Using
this approach, 144 candidate cross-reactive peptides were selected.
To test cross-reactivity, HLA transgenic mice were immunized
with individual arenavirus epitopes we had identified. Splenic
CD8
+ T cells were screened for IFN-c secretion in response to
APCs pulsed with either the immunizing epitope or the potentially
cross-reactive arenavirus peptides. Immunization with 5 HLA-
A*0201-restricted epitopes (JUNV GPC18–26, MACV GPC18–26,
LCMV GPC447–455, MACV NP19–27, and MACV NP432–440) and
2 HLA-A*1101-restricted epitopes (LCMV GPC46–55 and MACV
NP82–90) generated one or more cross-reactive CD8
+ T cell
response(s). It should be noted that the JUNV GPC18–26 and
MACV GPC18–26 epitopes have an identical amino acid sequence.
The remaining 19 HLA-restricted arenavirus epitopes did not
induce any detectable cross-reactive CD8
+ T cell responses.
Table 3 summarizes the results of these experiments.
The amino acid sequence differences between the epitope
sequence and the cross-reactive peptides mainly represented
conservative or semi-conservative amino acid substitutions occur-
ring at either the position 2 primary MHC interacting anchor
residue or the prominent secondary anchor residues at positions 1,
3, and 7 (Table 3). Thus, in general, the residues involved in TCR
Figure 3. Identification of naturally processed arenavirus-derived peptides in HLA-A*1101 transgenic mice following peptide
immunization. HLA-A*1101 transgenic mice were immunized s.c. with one of the listed peptides. After 11 to 14 days, splenocytes were restimulated
for 6 days with the immunizing peptide, and CD8
+ T cells were isolated. Effector CD8
+ T cells were exposed to human BVR cells that had been either
pulsed with 1 mg/ml of peptide, or infected with the appropriate rVACV in an ex vivo IFN-c ELISPOT assay. The dotted line indicates the threshold for
peptide positivity (net SFC/10
6 cells $20). Error bars indicate SD. Results are representative of at least two independent experiments.
doi:10.1371/journal.ppat.1000695.g003
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observed that non-cross-reactive peptides contained 3 or more
amino acid differences with the epitope sequence. As detailed in
Table 3, in terms of response magnitude, CD8
+ T cell responses to
the cross-reactive peptides ranged from 20–100% of the epitope-
specific response.
Table 2. Properties of arenavirus-derived HLA-A*1101-restricted CD8
+ T cell epitopes.
Arenavirus epitope
a Peptide sequence
% Identity to
parental species
b
Natural processing
in human APCs
c
Binding affinity
to A*1101 (nM)
d
GTOV L1977–1985 ATVKNVVLR 100 + 54
LCMV GPC46–55 LVSFLLLAGR 89 + 70
LCMV GPC112–120 FTNDSIISH 89 + 38
LCMV Z24–33 TTYLGPLSCK 94 + 2.8
MACV NP82–90 SIQKNTIFK 97 + 5.5
MACV Z27–36 RTAPPSLYGR 97 + 8.9
SABV GPC90–98 STYYVHENK 100 + 6.0
SABV NP82–90 SSQRDTILK 100 + 9.3
SABV Z64–72 KCLNIMLGK 100 + 678
WWAV NP439–447 SSIIRSLPK 100 + 2.5
aPeptide position within prototypic strains of arenavirus GPC, NP, L and Z proteins.
bAverage % amino acid identity of epitope sequence to all full-length isolate sequences within a given arenavirus species.
cEach peptide was screened for its ability to be endogenously processed and presented by HLA-A*1101. Purified CD8
+ T cells from peptide-immunized HLA-A*1101 mice
were tested for recognition of human BVR cells infected with the appropriate rVACV construct expressing one of the arenavirus proteins. +, Processed; 2, not processed.
dPeptides were tested for binding to the HLA-A*1101 allele. Bold font highlights biologically relevant binders (IC50#500 nM). 2, peptides with binding affinity .
5000 nM.
doi:10.1371/journal.ppat.1000695.t002
Table 3. Summary of cross-reactive arenavirus peptides.
Arenavirus Peptide
a Peptide sequence
b % of Epitope response
c Binding affinity to A*0201 or A*1101 (nM)
d
JUNV GPC18–26 ALNIALVAV 100 79
MACV GPC18–26 --------- 100 79
SABV GPC18–26 -I I----I I-- 23 834
WWAV GPC18–26 ------I I-- 74 27
LCMV GPC447–455 YLVSIFLHL 100 35
LASV GPC441–449 --I I------ 76 5.5
WWAV GPC428–436 -V VS------ 20 14
MACV NP19–27 GLSQFTHTV 100 18
JUNV NP19–27 ------Q Q-- 24 30
MACV NP432–440 AMPGVLSYV 100 8.4
GTOV NP432–440 -Q Q--L L---- 50 161
JUNV NP432–440 --------- 100 8.4
SABV NP433–441 -Q Q--L L---- 58 114
LCMV GPC46–55 LVSFLLLAGR 100 70
LASV GPC46–55 --T T----C C-- 147 - -
MACV NP82–90 SIQKNTIFK 100 5.5
SABV NP82–90 -S S-R RD--L L- 47 9.3
aPosition of epitope and cross-reactive peptide within prototypic strains of arenavirus GPC and NP.
bFull amino acid sequence is shown for epitope/immunizing peptide. Boldface letters indicate amino acid differences between epitope and cross-reactive arenavirus
peptide.
cCD8
+ T cells from peptide-immunized HLA-A*0201 and HLA-A*1101 transgenic mice were tested for their ability to produce IFN-c in response to HLA-restricted target
cells that had been pulsed with peptide. Percent of epitope response is calculated according to the formula: [(net spots/10
6 CD8
+ T cells against cross-reactive
peptide)/(net spots/10
6 CD8
+ T cells against epitope)6100]. Data are representative of at least two independent experiments.
dPeptides were tested for binding to their respective HLA allele. Bold font highlights biologically relevant binders (IC50#500 nM). 2, Peptides with binding affinity .
5000 nM. Binding affinities for LCMV GPC447–455, LASV GPC441–449, and WWAV GPC428–436 peptides are referenced from [10] and J. Botten and M. J. Buchmeier,
unpublished work.
doi:10.1371/journal.ppat.1000695.t003
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World arenaviruses, and in some cases, remained detectable even
with low doses (0.1 mg/ml) of peptide (Figure 4). However, the
LCMV GPC447–455 cross-reactivity spanned both Old (LASV) and
New (WWAV) World arenaviruses (data not shown). A cross-
reactive T cell response induced by LCMV GPC447–455 peptide
immunization has also been reported in an independent study (J.
Botten and M. J. Buchmeier, unpublished work). A total of 11 cross-
reactive peptides, including 3 previously defined epitopes and 8
newly identified peptides, were recognized in repeat experiments by
HLA-restricted epitope-specific CD8
+ T cells. Summed together, 36
arenavirus-derived peptides, which include 28 epitopes and 8 cross-
reactive peptides, generate arenavirus-specificCD8
+Tc e l lr e s p o n s e s
that recognize the 7 different arenavirus species (Table 4). Thus,
Figure 4. Immunization with arenavirus epitopes induces cross-reactive CD8
+ T cell responses. HLA-A*0201 transgenic mice were
immunized s.c. with either (A) JUNV/MACV GPC18–26, (B) MACV NP19–27, or (C) MACV NP432–440. Purified splenic CD8
+ T cells were isolated 11 to 14
days later and exposed to JA2.1 cells that had been pulsed with 10, 1 or 0.1 mg/ml of the orthologous arenavirus peptides in an ex vivo IFN-c ELISPOT
assay. Red line indicates immunizing epitope, blue line indicates cross-reactive peptides, and black line indicates non-cross-reactive peptides.
Responses were considered positive if the net SFC/10
6 CD8
+ T cells $20, the SI $2.0, and the statistical significance using a Student’s t test had a p-
value #0.05 at 10, 1 and 0.1 mg/ml of peptide in at least two independent experiments. The horizontal dashed line indicates the threshold for peptide
positivity (net SFC/10
6 cells $20). Error bars indicate SD. Results are representative of at least two independent experiments.
doi:10.1371/journal.ppat.1000695.g004
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coverage of the various HLA-virus combinations.
Population coverage afforded by the arenavirus epitopes
As expected, the majority of peptides bound to their restricting
allele with high affinity (IC50#500 nM; Tables 1 and 2). Thus,
our predictive approach effectively identified high affinity HLA
binding peptides. As HLA-A02 and A03 supertypes are
composed of a group of alleles that share largely overlapping
peptide binding specificities [21], we subsequently tested the
binding affinity of the identified arenavirus determinants to the
remaining HLA molecules found within each supertype. All of
the HLA-A*0201 determinants, except LASV GPC111–120,
bound 3 or more additional HLA-A02 supertype molecules
(HLA-A*0202, -A*0203, -A*0206, and -A*6802), and all HLA-
A*1101 determinants bound 3 or more additional HLA-A03
supertype molecules (HLA-A*0301, -A*3001, -A*3101, -A*3301,
and -A*6801) (data not shown).
Based on these results, we calculated the theoretical population
coverage afforded by the epitopes and cross-reactive peptides for
each of the 7 arenaviruses (using the Population Coverage
Calculation Tool available through the Immune Epitope Database
and Analysis Resource [22]). These calculations were based on
peptide binding data (shown in Tables 1, 2, and 3 and data not
shown) and the reported frequencies of each HLA allele in
different ethnic populations. For the present analysis, biologically
relevant binding was defined as an IC50#500 nM.
The total coverage of the general population provided by the
corresponding set of epitopes for each of the 7 different
arenaviruses is shown in Figure 5A. The epitopes identified from
LCMV and SABV provided the broadest population coverage of
69.9% of the overall population, while JUNV epitopes provided
the least amount of coverage of 36.3%. The remaining viruses,
GTOV, LASV, MACV, and WWAV, provided 59.8%, 43.6%,
67.1%, and 62.7% population coverage, respectively. When
averaged over the 7 different viruses, the defined epitopes provided
population coverage of 58.5% of the entire population. In most
cases, coverage entails recognition of multiple HLA-epitope
combinations. For example, from Figure 5A, it can be seen that
in an average population, about 35% of individuals can be
expected to recognize 3 or more epitope-HLA combinations.
Coverage was fairly balanced throughout the major ethnic
groups. A representative graph (Figure 5B) shows the coverage
afforded by the MACV peptides across several major population
groups. As shown, the MACV epitopes provide coverage ranging
from about 50.0% of Australians, to 88.5% for South Americans,
with an average coverage across all populations of 67.1%. These
results indicate that the set of arenavirus epitopes described in the
present study can provide broad coverage to the different viruses
in different ethnic populations.
Arenavirus epitope cocktail protects against rVACV
challenge
Lastly, we examined whether priming of HLA-A*0201
transgenic mice with a pool of the HLA-A02 arenavirus peptides
would confer protection against subsequent viral challenge.
Because challenge with 6 of the 7 different arenavirus species
considered would require BSL-4 containment, which was
unavailable to us, we utilized challenge with rVACVs expressing
the various arenavirus antigens as an alternative surrogate system.
Groups of HLA-A*0201 transgenic mice were immunized with
a pool of 14 CD8
+ T cell peptides plus a single T helper cell
epitope unrelated to arenaviruses, or mock-immunized (see
Materials and Methods for details). To ensure protection was
HLA-restricted, arenavirus peptides that were also restricted by
murine MHC (LASV111–120 and LCMV GPC34–43) and not
endogenously processed in human APCs (JUNV GPC7–15) were
excluded. Peptide-immunized mice were challenged with a
rVACV construct that expressed either LCMV GPC, LASV
GPC, or SABV GPC. On day 5 post-challenge, we observed that
peptide pool-immunized mice had significantly reduced mean
viral titers following challenge compared to the mock controls
(Figure 6A) with rVACV-LCMV GPC (2.0 log10 reduction;
P=0.0031), rVACV-LASV GPC (2.3 log10 reduction; P=0.0398),
and rVACV-SABV GPC (3.5 log10 reduction; P=0.0498).
Although the results obtained from mice challenged with
rVACV-LCMV GPC were quite consistent, we observed varying
viral titers in both mock and peptide-immunized mice challenged
with either rVACV-LASV GPC or rVACV-SABV GPC. This
could be due to technical failure in delivering the proper infectious
dose of these rVACV constructs during the i.p. inoculation.
Despite this variability, there still remains a significant difference
(P,0.05) between viral titers of the mock and peptide-immunized
mice that were challenged with rVACVs expressing either LASV
GPC or SABV GPC. We also found that the 3 different groups of
mock-immunized mice had varying viral titer levels. All rVACVs
utilized are capable of high titer replication both in vitro and in vivo.
We have, however, observed that certain rVACVs (i.e. rVACV-
SABV GPC) grow more efficiently compared to others (i.e.
rVACV-LCMV GPC). This might help explain the differences
observed in viral titers in mock-immunized mice challenged with
the 3 rVACVs (Figure 6A).
To determine whether an expansion of epitope-specific CD8
+ T
cells after rVACV challenge would correlate with viral titer
reduction, the frequency of epitope-specific CD8
+ T cells following
peptide pool immunization before and after rVACV challenge was
measured. At 18 days post-peptide pool immunization, HLA-
A*0201 transgenic mice that were not challenged displayed
significant numbers of CD8
+ T cells to all immunizing epitopes
(Figure 6B). However, mice that were peptide pool immunized
and challenged with an rVACV-GPC demonstrated a clear
expansion of CD8
+ T cells specific for the challenge virus. In some
instances, cross-reactive CD8
+ T cell expansion was also observed.
For example, LASV GPC441–449-specific CD8
+ T cells expanded
following challenge with rVACV-LCMV GPC. Thus, these results
demonstrate that CD8
+ T cell-mediated immunity can protect
against challenge with rVACVs expressing Old and New World
arenavirus antigens in an epitope-specific manner.
Discussion
Hemorrhagic fever and aseptic meningitis caused by arenavirus
infection represent serious human public health problems that lead
to dehabilitating and sometimes fatal disease. Furthermore,
arenaviruses are regarded as a potential bioterrorism threat, and
Table 4. Summary of HLA epitope coverage amongst 7
pathogenic arenaviruses.
HLA GTOV JUNV LASV LCMV MACV SABV WWAV Total
A*0201 1 4 4 5 3 4 4 25
A*1101 1 0 1 3 2 3 1 11
Total 2 4 5 8 5 7 5 36
Includes the sum of the arenavirus-derived epitopes and cross-reactive peptides
defined in the present study, and the HLA-A*0201-restricted LASV and LCMV
epitopes identified in previous studies [9,10].
doi:10.1371/journal.ppat.1000695.t004
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vaccine against arenavirus infection needs to address the genetic
diversity observed within and between different viral species of the
Arenaviridae family. Indeed, pathogen heterogeneity is also a
prominent consideration among other families of RNA viruses.
For instance, the genetic variability found amongst HIV clades
circulating worldwide, and the high mutation rate of HIV that
allows for evasion of the adaptive immune response, continue to
provide a daunting challenge for vaccine development [23].
Likewise, HCV vaccine design faces the obstacle of different
genotypes that are found with different prevalence in distinct
locations [24]. The four dengue virus serotypes provide a unique
challenge, as heterologous re-infection is associated with dengue
hemorrhagic fever and dengue shock syndrome [25,26]. The
variability associated with influenza virus is reflected in different
strains and subtypes, forcing the development of yearly updated
vaccines, and is also the cause of concern in the context of new
influenza pandemics [27,28].
Figure 5. The identified epitopes and cross-reactive peptides provide broad population coverage. The theoretical population coverage
was calculated based on the binding affinity data for each HLA-A02 and HLA-A03-restricted epitope and cross-reactive peptide as well as the
reported frequencies of each HLA allele in different ethnic populations. A biologically relevant binding was defined as an IC50#500 nM [19]. (A) The
average population coverage for each of the 7 arenaviruses. The horizontal dashed line indicates that 58.5% of the population, on average,
recognizes one or more arenavirus peptide. (B) For MACV, shown as representative data, the number of possible peptide-HLA allele combinations as
a function of the fraction of each ethnic population (%) is shown. The horizontal dashed line represents the fraction of individuals (67.1%) that
recognize one or more MACV peptide in an average population.
doi:10.1371/journal.ppat.1000695.g005
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PLoS Pathogens | www.plospathogens.org 9 December 2009 | Volume 5 | Issue 12 | e1000695Figure 6. Protection against rVACV challenge is arenavirus epitope-specific in HLA-A*0201 transgenic mice. Female HLA-A*0201
transgenic mice were immunized with a pool of 15 peptides, including 14 arenavirus peptides plus the HBV core128–140 helper epitope, or with
adjuvant and helper epitope alone (mock). On day 13 post-immunization, mice were inoculated i.p. with 10
7 PFU of either rVACV-LCMV GPC, rVACV-
LASV GPC, or rVACV-SABV GPC. (A) Ovaries were harvested 5 days after challenge, and viral titers were determined via plaque assay. Individual viral
titers are shown and the horizontal line represents the mean titer for each group. When no plaque growth was detected, values were set at a
threshold of detection (log10 pfu/g tissue=3.0). Mean viral titers from the peptide-immunized group were compared to the mock group using the
Mann-Whitney t test to determine if differences were significant. (B) On day 18 post-immunization, splenic CD8
+ T cells were isolated from mice that
were immunized with peptide alone, immunized with peptide and challenged with a rVACV 5 days previous to the assay, or immunized with
adjuvant and challenged with a rVACV. CD8
+ T cells were stimulated with peptide (0.1 mg/ml) pulsed JA2.1 cells in an ex vivo IFN-c ELISPOT assay.
Error bars indicate SD. Results are an average of two independent experiments.
doi:10.1371/journal.ppat.1000695.g006
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within a family will be developed, the two most viable, and not
necessarily exclusive, approaches might be the development of
either a multivalent and/or a cross-protective vaccine. Herein, we
performed proof of concept studies to evaluate these approaches,
utilizing arenaviruses as a model system. Our results indicate that
multiple conserved (89 to 100%) epitopes can be defined from
each arenavirus. While broadly cross-reactive epitopes between
arenavirus species were not identified, occasional cross-reactivites
were demonstrated, leading to an increased viral coverage by the
defined epitope set. Notably, it was possible to induce simulta-
neous responses against all epitopes by a peptide pool vaccination,
demonstrating the feasibility of a multivalent vaccination. This
shows that a single vaccination strategy with both multivalent and
cross-protective CD8
+ T cell epitopes was able to engender
protection from recombinant viruses expressing antigens derived
from a subset of different arenavirus species. Because our study
was focused on demonstrating universal coverage against multiple
arenavirus species, we chose to conduct protection studies utilizing
rVACVs expressing antigens from 3 representative arenavirus
species. Protection from virus challenge was demonstrated through
reduced viral titers in peptide-immunized animals instead of
survival, as the rVACVs used in this study are attenuated viruses.
Previous studies utilizing animal models of HIV and influenza
infection have demonstrated that a reduction in viremia correlates
with survival [29,30]. Importantly, we have also shown in an
independent study that immunization with LCMV GPC447–455
protected HLA-A*0201 transgenic mice against lethal intracranial
challenge with LCMV [31].
To identify HLA-restricted CD8
+ T cell epitopes derived from
pathogenic arenaviruses, certain technical challenges needed to be
circumvented, including the need for BSL-4 containment for most
species considered, and the lack of availability of samples from
exposed human donors. We bypassed the requirement for BSL-4
containment by developing a panel of 24 rVACV vectors that
expressed the different arenavirus antigens of interest. To our
knowledge, this is the first instance in which this approach has
been implemented on a large scale to study T cell responses
directed against human pathogens. In addition, utilizing HLA
transgenic mice enabled the identification of epitopes relevant for
humans. HLA transgenic mice have been useful in identifying
human T cell epitopes from small viruses, such as influenza [32],
and more complex pathogens, such as VACV [33]. In the future,
we plan to examine CD8
+ T cell responses in arenavirus-immune
human donors in order to assess the degree of overlap between
arenavirus-specific responses recognized in HLA transgenic mice
and humans.
In total, 16 HLA-A*0201, and 10 HLA-A*1101, arenavirus-
specific CD8
+ T cell epitopes that are naturally processed by
human APCs have been identified so far. These numbers are
similar to those found in other virus infection models. For
example, we previously identified 14 HLA-A*0201, 4 HLA-
A*1101, and 3 HLA-B*0702-restricted VACV-specific CD8
+ T
cell epitopes using HLA transgenic mice [34]. In additional studies
in H-2
b mice, 19 H-2K
b and 9 H-2D
b-restricted LCMV-specific
epitopes were identified [8]. In the VACV system, 27 H-2K
b and
22 H-D
b-restricted epitopes were defined [35]. It is important to
point out that our current study was not designed to identify the
totality of the response, but rather focused on epitopes relatively
well conserved within a given arenavirus species.
Widely conserved CD8
+ T cell epitopes among the 7
different arenaviruses species were not identified. Given that
amino acid sequence identities of homologous proteins of the 7
arenavirus species range from 44 to 63% [36], it is not
surprising that only a few conserved epitopes were identified.
However, we found that immunization of HLA transgenic
mice with 7 of the arenavirus peptides induced cross-reactive
CD8
+ T cell responses, which significantly increased the
coverage afforded by the epitope set against different
arenavirus species. Importantly, T cell cross-reactivity might
also extend to newly identified arenaviruses. To examine this
further, we compared the amino acid sequence of the epitopes
defined here to the orthologous regions within Chapare [37]
and Lujo [38] viruses. We found that 6 of the identified
epitopes had $70% amino acid sequence identity to the
Chapare and Lujo viruses. Thus, cross-reactive T cells might
also extend to peptides derived from newly discovered
arenaviruses.
Previous studies have demonstrated T cell cross-reactivity for
both Old and New World arenaviruses. It was shown in a guinea
pig model that adoptive transfer of LCMV or Moepia virus
(MOPV)-immune CD8
+ T cells could confer protection against
challenge with the highly virulent LASV [39]. Likewise, in a
murine model, cell transfer of LCMV-immune CD4
+ and CD8
+ T
cells protected mice from Pichinde virus infection [40]. Further-
more, in humans, T cell clones from patients that have recovered
from acute LASV infection showed cross-reactive recognition of
MOPV peptides [41]. Inter-clade cross-reactivity has also been
demonstrated for HIV-specific CD8
+ T cell responses and is
considered of particular relevance in vaccines that are to be used
in geographically and genetically distinct HIV epidemics
[42,43,44].
We demonstrated that the arenavirus epitope set afforded
redundant coverage of the different viruses by epitopes of different
restriction, as an average about 50% of individuals are predicted to
recognize more than one MHC-peptide combinations. Coverage
of approximately 60% of the general population is projected on
the basis of HLA frequencies and binding data. As only 2 HLA
supertypes were investigated, it should be possible to achieve
essentially 100% coverage by identifying epitopes restricted by
additional supertypes, such as A01, A24, B07, and B44 [16,21].
Herein, we implemented a multivalent vaccine strategy to
protect against rVACVs expressing antigens from different
arenavirus species. This approach has proven itself in the case of
the currently licensed vaccine against HPV, which contains capsid
proteins derived from 4 different serotypes prominently associated
with disease [45]. We demonstrated that immunization of HLA-
A*0201 transgenic mice with a cocktail containing 14 arenavirus-
derived peptides and a T helper cell epitope resulted in a
detectable CD8
+ T cell response to each of the viral epitopes. The
magnitude of epitope-specific CD8
+ T cell responses following
peptide pool immunization was diminished compared to the
responses observed after individual peptide immunization (see
Figures 2 and 6B for comparison). Competition for HLA-A*0201
binding might play a role in determining the response magnitude
of epitopes when immunized as a pool. However, the magnitude of
the CD8
+ T cell responses was sufficient to significantly reduce
viral titers following challenge with rVACVs expressing both Old
and New World arenavirus antigens.
Furthermore, comparing our data to a previous study, we found
that the coverage achieved with the breadth of epitopes does not
compromise immunity to a single epitope. HLA-A*0201 trans-
genic mice immunized with the pool of the 14 arenavirus-specific
determinants and challenged with rVACV-LASV GPC demon-
strated a 2.3-log reduction in viral titers compared to the mock
control. Botten et al. demonstrated that single peptide immuniza-
tion of HLA-A*0201 transgenic mice with either LASV GPC42–50
or GPC60–68, two epitopes included in our peptide pool
Vaccine Strategy against Pathogenic Arenaviruses
PLoS Pathogens | www.plospathogens.org 11 December 2009 | Volume 5 | Issue 12 | e1000695immunization, followed by challenge with rVACV-LASV GPC
resulted in a 2.8 and 2.2-log reduction in viral titers, respectively
[9]. Thus, viral titer reduction is very similar whether mice are
immunized with a single epitope or an epitope cocktail.
None of the defined arenavirus epitopes demonstrated cross-
reactivity with VACV-WR, strongly suggesting that the reduction
in viral titers in peptide-immunized mice is mediated by
arenavirus-specific CD8
+ T cell responses (see Figure 1 for
representative data). To provide further evidence for arenavirus
epitope-specific protection, we observed a substantial expansion of
CD8
+ T cell responses specific for the challenge virus (relative to
unchallenged mice). Furthermore, Botten et al. demonstrated that
immunization of HLA-A*0201 transgenic mice with either LASV
GPC42–50 or GPC60–68 did not result in protection against
challenge with the irrelevant rVACV-LASV NP construct,
confirming the protection following rVACV-LASV GPC chal-
lenge was LASV epitope-specific [9].
We also found cross-reactive CD8
+ T cell responses were
significantly boosted following rVACV challenge of peptide pool-
immunized mice. As expected, the LCMV GPC447–455-specific
CD8
+ T cell response was boosted following rVACV-LASV GPC
challenge, while challenge with rVACV-LCMV GPC boosted the
CD8
+ T cell response against LASV GPC441–449. The LCMV
GPC10–18-specific CD8
+ T cell response expanded approximately
40-fold following rVACV-LASV GPC challenge, while only 3-fold
after challenge with rVACV-LCMV GPC. One possible expla-
nation for this discrepancy is that the expanded CD8
+ T cell subset
generated following rVACV-LASV GPC challenge has a higher
avidity for the LCMV peptide. Finally, mice immunized with the
peptide pool and challenged with the rVACV expressing SABV
GPC showed a significant expansion of CD8
+ T cells with the
SABV NP547–556 peptide. It is plausible that infection with
rVACV-SABV GPC led to the generation of a cross-reactive
CD8
+ T cell subset that was capable of recognizing the SABV
NP547–556 peptide.
In conclusion, our studies suggest that simultaneous induction of
a multivalent and cross-protective CD8
+ T cell response is a
feasible approach to vaccination against multiple arenavirus
species. As a proof of concept, protection studies with rVACVs
expressing the GPC from LCMV, LASV, and SABV were
performed. Additional studies are still required to investigate
whether peptide pool immunization would reduce viral titers in
transgenic mice challenged with rVACVs expressing other
arenavirus GPCs (GTOV, JUNV, MACV, and WWAV), or
other arenavirus proteins (NP and/or Z). The identification of
epitopes restricted by additional HLA types, their validation in
humans exposed to arenavirus infections, and their formulation in
a multivalent construct would also be the logical next steps in the
further exploration of this concept.
Materials and Methods
Ethics statement
All mouse studies followed guidelines set by the National
Institutes of Health and the Institutional Animal Care and Use
Committee-approved animal protocols (Association for Assess-
ment and Accreditation of Laboratory Animal Care International
(AAALAC) and Office of Laboratory Animal Welfare (OLAW)).
Bioinformatic analyses
The arenavirus open reading frames (ORFs) utilized in this
study were a total of 333 unique sequences from one or more
isolates of GTOV, JUNV, LASV, LCMV, MACV, SABV,
and WWAV taken from the arenavirus protein sequence
database (http://epitope.liai.org:8080/projects/arena) [36]. Can-
didate HLA-A02 and A03 supertype epitopes were identified using
a previously described algorithm [15]. Peptides with a predicted
IC50#100 nM were selected from each ORF, and then ranked
based on inter-virus conservancy (% identity matches). The top
ranked peptides (up to 30) per supertype per virus per antigen
were selected.
Peptide synthesis
Peptides were synthesized as crude material by Pepscan Systems
(Lelystad, The Netherlands). Candidate epitopes were resynthe-
sized by A and A Labs (San Diego, CA) and purified to 95% or
greater homogeneity by reverse-phase HPLC. Hepatitis C virus
core 132 (DLMGYIPLV), and human MAGE 369
(SSLPTTMNY) were used as control HLA-A*0201 and HLA-
A*1101-restricted peptides, respectively. IEDB submission identi-
fication numbers for HLA-A*0201 and HLA-A*1101-restricted
epitopes are 1000381 and 1000374, respectively.
MHC peptide-binding assay
Quantitative assays to measure the binding affinity of peptides
to purified HLA-A02 (A*0201, A*0202, A*0203, A*0206, A*6802)
and HLA-A03 (A*1101, A*0301, A*3001, A*3101, A*3301,
A*6801) supertype molecules were based on the inhibition of
binding of a radiolabeled standard peptide, and were performed
essentially as described elsewhere [46,47,48]. Briefly, after a 2-day
incubation, binding of the radiolabeled peptide to the correspond-
ing MHC class I molecule was determined by capturing MHC/
peptide complexes on Greiner Lumitrac 600 microplates (Greiner
Bio-One, Monroe, NC) coated with the W6/32 Ab (anti-HLA
class I), and measuring bound cpm using the Topcount
microscintillation counter (Packard Instrument). The concentra-
tion of peptide yielding 50% inhibition of the binding of
the radiolabeled probe peptide (IC50) was then calculated. Peptides
were typically tested at six different concentrations covering a
100,000-fold dose range, and in three or more independent assays.
Under the conditions utilized, where [label] , [MHC] and
IC50 $ [MHC], the measured IC50 values are reasonable
approximations of the KD values.
Mice
HLA-A*0201/K
b and HLA-A*1101/K
b (referred to as HLA-
A*0201 and HLA-A*1101) transgenic mice were bred and
maintained in the animal facilities at the La Jolla Institute for
Allergy and Immunology (La Jolla, CA). These mice were the F1
generation derived from a cross between BALB/c mice (The
Jackson Laboratory, Bar Harbor, ME) and HLA transgenic mice
(expressing a chimeric gene consisting of the a1 and a2 domains of
the human HLA and the a3 domains of murine H-2K
b) created
on the C57BL/6J background [17,18]. CB6F1/J mice were the F1
generation derived from a cross between C57BL/6J and BALB/c
mice (The Jackson Laboratory). C57BL/6J mice deficient in K
b
and D
b (K
bD
b2/2) mice were purchased from Taconic Farms
(Hudson, NY).
Cells
Target cells used in the IFN-c ELISPOT assays were the
human Jurkat cells (JA2.1) that express the HLA-A*0201/K
b
chimeric gene [17], human EBV B cells (BVR) that express HLA-
A*1101, and LPS-stimulated B lymphoblasts prepared as previ-
ously described [34] from HLA-A*0201 and HLA-A*1101
transgenic mice, and CB6F1/J (H-2
bxd) mice, which do not
express the HLA transgene. The target cells were either pulsed for
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7 PFU
rVACV, or 2610
6 PFU VACV-WR 24 h prior to the ELISPOT
assay. CV-1 (CCL-70), Vero E6 (CRL-1586), BHK-21 (CCL-10),
and BSC-40 (CRL-2761) cells were purchased from ATCC and
grown as recommended by the supplier.
Viruses
The rVACV-LCMV GPC and NP (derived from LCMV
Armstrong Clone 53b) constructs were engineered using the WR
strain of VACV as previously described [49]. LCMV GPC and
NP gene expression were under the control of the VACV P7.5K
early/late promoter [49]. The remaining rVACV arenavirus
constructs were also generated on the WR background using ORF
sequences from prototypic arenavirus strains (as outlined in Table
S1), according to the protocols established by Blasco and Moss
[50]. Arenavirus target gene expression was under the control of a
synthetic early/late promoter, PSYN [50]. In brief, the arenavirus
GPC, NP, L, and Z genes were subcloned individually into the
pRB21 transfer vector. CV-1 cells were then infected with the
VACV strain vRB12 at an MOI of 2, followed by transfection with
10 mg of the transfer vector containing a single arenavirus ORF.
Viruses that underwent homologous recombination with the
transfer vector were selected for their plaque-forming ability.
Arenavirus protein expression was confirmed for each rVACV
through immunoflourescence assay to verify that all plaques
expressed the correct antigen, as well as by Western blot analysis
to verify the correct processing and size of each arenavirus
protein. Virus titers were determined through plaque assays on
BSC-40 cells.
Immunizations and viral challenge
For epitope identification studies, HLA-A*0201 and HLA-
A*1101 transgenic mice were peptide-immunized s.c. at the base
of the tail with a pool of 8 to 11 peptides (15 mg/peptide) or 50 mg
of a single peptide, along with 140 mg of the helper I-A
b-restricted
epitope hepatitis B virus (HBV) core128–140 (TPPAYRPPNAPIL)
in PBS emulsified in IFA. In general, effector CD8
+ responses
were analyzed in the spleens of mice 11 to 14 days after peptide
immunization. One exception was the assessment of processing of
the HLA-A*1101 peptides. In this case, effector CD8
+ responses
were analyzed by utilizing splenocytes from single peptide-
immunized mice that were cultured in vitro for an additional 6
days with the immunizing peptide. For VACV infection, HLA-
A*0201 transgenic mice were injected i.p. with either 2610
6 PFU
VACV-WR strain as a control, or 10
7 PFU rVACV containing
one of the arenavirus genes. A higher dose of 10
7 PFU rVACVs
was used because these viruses are attenuated, while wt VACV-
WR is not. The infectious doses of 2610
6 PFU VACV-WR and
10
7 PFU rVACV have been routinely used in previous studies
[9,31,34]. On day 7 post-infection, mice were sacrificed and
purified splenic CD8
+ T cells were analyzed by ex vivo ELISPOT
assays for IFN-c.
For challenge studies, HLA-A*0201 transgenic mice immunized
with a pool of 15 peptides, including 14 arenavirus epitopes
(50 mg/peptide) and 140 mg of the HBV core128–140 helper
epitope, in PBS emulsified in IFA, or mock-immunized with an
equivalent volume of DMSO as the peptide-immunized group as
well as 140 mg of the helper epitope in PBS emulsified in IFA.
Mice were challenged 13 days later through i.p. inoculation with
10
7 PFU rVACV-LCMV GPC, rVACV-LASV GPC, or rVACV-
SABV GPC. Five days after virus challenge, spleens were
harvested for CD8
+ T cells and ovaries were harvested for
rVACV titer determination. To quantitate viral titers, ovaries were
homogenized and sonicated prior to plating serial 10-fold dilutions
of the homogenates on BSC-40 cells.
IFN-c ELISPOT assay
The mouse IFN-c ELISPOT assay was performed as previously
described [51]. In brief, 4610
5 splenocytes or 2610
5 splenic CD8
+
T cells (purified by anti-CD8 magnetic beads [Miltenyi Biotec,
Auburn, CA]) were cultured with either 10
4 or 10
5 peptide-pulsed
or rVACV-infected target cells. For peptide pulsing, target cells
were incubated with peptide for at least 1 h at 37uC, followed by 3
washes to remove excess peptide. For rVACV infection, JA2.1 or
BVR cells were infected at a MOI of 10 with a rVACV 18 to 20 h
prior to the assay. Each assay was performed in triplicate wells.
After a 20 h incubation at 37uC, plates were developed, and
responses calculated as described [34]. Criteria for positivity were
net spot-forming cells (SFC)/10
6 cells $20, stimulation index
(SI) $1.4 or 2.0, and p-value #0.05 using a Student’s t test in at
least 2 out of 3 experiments.
Supporting Information
Figure S1 Expression of GTOV antigens from rVACV
constructs. BSC-40 cells were infected with rVACV encoding
the GTOV NP, GPC, L, or Z proteins or wt VACV and 24 hr
later protein lysates were generated from infected cells. Protein
lysates were run on a 4–20% tris-glycine acrylamide gel,
transferred onto a nitrocellulose membrane, and probed via
Western blot with an anti-HA antibody to detect the presence of
GTOV NP, GPC/GP2, L, and Z (all of which contained a C-
terminal HA tag). Two protein bands are detected in the rVACV-
GTOV GPC cell lysate; the upper band is GPC and the lower
band is GP2, the post-translational cleavage product of GPC. The
size of the molecular weight markers in kiloDaltons is indicated on
the left-hand side of the blot.
Found at: doi:10.1371/journal.ppat.1000695.s001 (0.36 MB PDF)
Table S1 Arenavirus strain sequences used to generate rVACV
constructs expressing the GPC, L, NP, or Z protein.
Found at: doi:10.1371/journal.ppat.1000695.s002 (0.05 MB PDF)
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